An investigational vaccine seems to be effective against the most common strain of norovirus and has been found to reduce the main symptoms of the gastrointestinal (GI) infection, vomiting and/or diarrhea, by 52 percent.
A a research has suggested this. Currently, there is no treatment or cure for norovirus, the most common cause of severe GI infection in the US.
Clinical Trials for Norovirus Vaccine on the Anvil
Two different groups of researchers in the United States are hoping to conduct clinical trials for their vaccines against the highly infectious norovirus.
Advertisement
Lead author David I. Bernstein, MD, MA, professor of pediatrics at Cincinnati Children's Hospital Medical Center and the University of Cincinnati, said that norovirus truly is a global issue and most if not everyone has experienced it to some degree.
The randomized, multi-center study included 98 people who agreed to drink water containing a significant dose of the virus, 50 who received the injected vaccine and 48 who received a placebo injection that did not contain the vaccine.
![LigoCyte's Norovirus Vaccine Demonstrates Protection Against Illness: NEJM Study]( "LigoCyte's Norovirus Vaccine Demonstrates Protection Against Illness: NEJM Study")
An experimental vaccine manufactured by LigoCyte Pharmaceuticals, Inc. provided significant protection against norovirus infection
Neither the participants nor the researchers knew in advance who received the vaccine and who did not. In the vaccine group, 26 (52 percent) were infected, as were 29 (60 percent) of those in the non-vaccine group.
In people who received the vaccine, 10 (20 percent) suffered from mild, moderate or severe vomiting and/or diarrhea versus 20 (42 percent) in the non-vaccine group, a 52 percent reduction in symptoms.
Source: ANI
LigoCyte's Norovirus Vaccine Demonstrates Protection Against Illness: NEJM Study
An experimental vaccine manufactured by LigoCyte Pharmaceuticals, Inc. provided significant protection against norovirus infection
Advertisement
Neither the participants nor the researchers knew in advance who received the vaccine and who did not. In the vaccine group, 26 (52 percent) were infected, as were 29 (60 percent) of those in the non-vaccine group.
In people who received the vaccine, 10 (20 percent) suffered from mild, moderate or severe vomiting and/or diarrhea versus 20 (42 percent) in the non-vaccine group, a 52 percent reduction in symptoms.
Source: ANI
Contamination With Norovirus High in Fresh Fruits and Vegetables
The risk of contamination with norovirus is high in fresh fruits and vegetables especially in the event of exposure to water that is used to dilute pesticides, a recent insight has revealed.
Advertisement
 New Strain of Norovirus Implicated in Stomach Flu Cases in USThe CDC revealed that a new strain of norovirus was responsible for more than half of "stomach flu" cases in the USA over the last month. | Advertisement
|
Advertisement
Recommended Readings
Latest Research News
Researchers establish connections between Alzheimer's-linked genetic alterations and the functioning of brain cells.
Team at NeuroRestore introduces a groundbreaking gene therapy that has effectively promoted nerve regrowth and reconnection, post spinal cord injury.
Scientists aim to pinpoint particular functional pathways affected by these bacteria that may have an impact on skeletal health.
Consuming a diet rich in saturated fats triggers persistent, low-level inflammation within the body, ultimately contributing to the onset of metabolic syndrome.
Ae. aegypti mosquitoes are carriers of "arthropod-borne" or "arbo-" viruses, which encompass the dengue virus, yellow fever virus, Zika virus, and chikungunya virus.
